IL-17 Inhibition: A Targeted Approach to the Management of Psoriatic Arthritis

In this downloadable slideset, Dafna D. Gladman, MD, FRCPC, reviews the role of IL-17A in psoriatic arthritis and examines key data surrounding the use of IL-17–targeted therapies to treat this condition.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.42 MB
Released: October 7, 2016

Acknowledgements

Supported by an educational grant from
Lilly USA, LLC

Related Content

Slides featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Released: February 8, 2022

Interactive video roundtable featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis.

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Nurse Practitioners: 0.75 NAPNAP CE contact hour, 0.25 pharmacology content Released: February 7, 2022 Expired: February 6, 2023

Expert insights from ACR 2021, including the most important data to clinical practice on the management of axPsA and axSpA, from Clinical Care Options (CCO)

Philip Mease, MD, MACR Released: December 23, 2021

Expert insights from ACR 2021, including the most important data for clinical practice on the management of axSpA and axPsA, from Clinical Care Options (CCO)

Atul Deodhar, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 22, 2021 Expired: December 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings